Gaucher's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018SummaryGlobalData, the industry analysis specialist, has released its new report, 'Gaucher's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018'. The report is an essential source of information and analysis on the global Gaucher's Disease Therapeutics market. The report identifies the key trends shaping and driving the global Gaucher's Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gaucher's Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.ScopeThe report provides information on the key drivers and challenges of the Gaucher's Disease Therapeutics market. Its scope includes - - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Gaucher's Disease Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.- Analysis of the current and future competition in the seven key countries Gaucher's Disease Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Gaucher's Disease Therapeutics market.- Analysis of key recent licensing and partnership agreements in Gaucher's Disease Therapeutics marketReasons to buyThe report will enhance your decision making capability. It will allow you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Gaucher's Disease Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Gaucher's Disease Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What's the next big thing in the global Gaucher's Disease Therapeutics market landscape' ' Identify, understand and capitalize.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Gaucher's Disease Therapeutics - Pipeline Assessment and Market
Forecasts to 2018
Published on January 2012
Report Summary
Gaucher's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, 'Gaucher's Disease Therapeutics - Pipeline Assessment and
Market Forecasts to 2018'. The report is an essential source of information and analysis on the global Gaucher's Disease
Therapeutics market. The report identifies the key trends shaping and driving the global Gaucher's Disease Therapeutics market. The
report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the
market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products
within the global Gaucher's Disease Therapeutics sector. This report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Gaucher's Disease Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Gaucher's Disease Therapeutics market
revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by
seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Gaucher's Disease Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a
qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the
Gaucher's Disease Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Gaucher's Disease Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by
identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Gaucher's Disease Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to
impact the global Gaucher's Disease Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of
various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive
advantage.
Gaucher's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 1/7

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities
for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Gaucher's Disease Therapeutics market landscape' ' Identify, understand and capitalize.
Table of Content
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Gaucher's Disease Therapeutics - Introduction 7
2.1 Disease Overview 7
2.1.1 Types of Gaucher's Disease 7
2.2 Epidemiology 8
2.3 Etiology 8
2.4 Pathophysiology 8
2.5 Signs and Symptoms 8
2.5.1 Type 1 Gaucher's Disease Clinical Manifestation 8
2.5.2 Type 2 Gaucher's Disease Clinical Manifestation 9
2.5.3 Type 3 Gaucher's Disease Clinical Manifestation 9
2.6 Commonly Used Diagnostic Tests 9
2.6.1 Commonly Diagnostic Tests 9
2.7 Treatment and Management Options for Gaucher's Disease 10
2.7.1 Types of Therapeutics Options 10
2.8 GlobalData Pipeline Report Guidance 11
3 Gaucher's Disease Therapeutics - Market Characterization 12
3.1 Gaucher's Disease Therapeutics Market Size (2005 - 2010) - Global 12
3.2 Gaucher's Disease Therapeutics Market Forecast (2010 - 2018) - Global 13
3.3 Gaucher's Disease Therapeutics Market Size (2005 - 2010) - The US 15
3.4 Gaucher's Disease Therapeutics Market Forecast (2010 - 2018) - The US 16
3.5 Gaucher's Disease Therapeutics Market Size (2005 - 2010) - France 17
3.6 Gaucher's Disease Therapeutics Market Forecast (2010 - 2018) - France 18
3.7 Gaucher's Disease Therapeutics Market Size (2005-2010) - Germany 19
3.8 Gaucher's Disease Therapeutics Market Forecast (2010 - 2018) - Germany 20
3.9 Gaucher's Disease Therapeutics Market Size (2005 - 2010) - Italy 21
3.10 Gaucher's Disease Therapeutics Market Forecast (2010 - 2018) - Italy 22
3.11 Gaucher's Disease Therapeutics Market Size (2005 - 2010) - Spain 23
3.12 Gaucher's Disease Therapeutics Market Forecast (2010 - 2018) - Spain 24
3.13 Gaucher's Disease Therapeutics Market Size (2005 - 2010) - The UK 25
3.14 Gaucher's Disease Therapeutics Market Forecast (2010 - 2018) - The UK 26
3.15 Gaucher's Disease Therapeutics Market Size (2005 - 2010) - Japan 27
3.16 Gaucher's Disease Therapeutics Market Forecast (2010 - 2018) - Japan 28
3.17 Drivers and Barriers for the Gaucher's Disease Therapeutics Market 29
3.17.1 Drivers for the Gaucher's Disease Therapeutics Market 29
3.17.2 Barriers for the Gaucher's Disease Therapeutics Market 29
3.18 Opportunity and Unmet Need Analysis 30
Gaucher's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 2/7

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
3.19 Key Takeaway 31
4 Gaucher's Disease Therapeutics - Competitive Assessment 32
4.1 Overview 32
4.2 Strategic Competitor Assessment 32
4.3 Product Profiles for the Marketed Products in the Gaucher's Disease Therapeutics Market 33
4.3.1 Cerezyme (imiglucerase) 33
4.3.2 Zavesca (miglustat) 34
4.3.3 Vpriv (velaglucerase alfa) 35
4.4 Key Takeaway 36
5 Gaucher's Disease Therapeutics - Pipeline Assessment 37
5.1 Overview 37
5.2 Strategic Pipeline Assessment 37
5.3 Gaucher's Disease Therapeutics Pipeline - Pipeline by Phases of Development 37
5.3.1 Gaucher's Disease Therapeutics - Regulatory Filed and Phase III Clinical Pipeline 38
5.3.2 Gaucher's Disease Therapeutics - Phase II Pipeline 38
5.3.3 Gaucher's Disease Therapeutics - Preclinical 38
5.4 Technology Trends Analytic Framework 39
5.5 Gaucher's Disease Therapeutics Market - Pipeline by Mechanism of Action 40
5.6 Gaucher's Disease Therapeutics - Promising Drugs in Clinical Development 40
5.7 Molecule Profile for Promising Drugs in Clinical Development 41
5.7.1 Uplyso (taliglucerase alfa) 41
5.7.2 Eliglustat tartrate(Genz-112638) 42
5.7.3 ISU302 42
5.8 Key Takeaway 43
6 Gaucher's Disease Therapeutics - Clinical Trials Mapping 44
6.1 Clinical Trials by Region and Country 44
6.2 Clinical Trials by Phase 45
6.3 Clinical Trials by Trial Status 46
6.4 Clinical Trials Mapping by Sponsors 47
6.5 Prominent Sponsors 48
6.6 Top Companies Participating in Gaucher's Disease Therapeutics Clinical Trials 49
7 Gaucher's Disease Therapeutics - Strategic Assessment 50
7.1 Key Events Impacting the Future Market 50
7.2 Gaucher's Disease Therapeutics - Implications for Future Market Competition 51
8 Gaucher's Disease Therapeutics Market - Future Players 52
8.1 Introduction 52
8.2 Company Profiles 52
8.2.1 Pfizer Inc. 52
8.2.2 Protalix BioTherapeutics, Inc. 54
8.2.3 ISU ABXIS Co., Limited 54
8.2.4 Sanofi 55
8.2.5 Actelion Limited 56
8.2.6 Shire Plc 57
9 Gaucher's Disease Therapeutics - Licensing and Partnership Deals 59
10 Gaucher's Disease Therapeutics - Appendix 61
10.1 Market Definitions 61
10.2 Acronyms 61
10.3 Research Methodology 62
Gaucher's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 3/7

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
10.3.1 Coverage 62
10.3.2 Secondary Research 62
10.3.3 Forecasting 63
10.3.4 Primary Research 65
10.3.5 Expert Panel Validation 65
10.4 Contact Us 65
10.5 Disclaimer 65
10.6 Bibliography 66
List of Tables
Table 1: Clinical Subtypes and Manifestations of Gaucher's Disease 7
Table 2: Clinical Manifestations of Gaucher's Disease 9
Table 3: Gaucher's Disease Therapeutics Market, Global, Revenue ($m), 2005 - 2010 12
Table 4: Gaucher's Disease Therapeutics Market, Global, Forecast ($m), 2010 - 2018 14
Table 5: Gaucher's Disease Therapeutics Market, The US, Revenue ($m), 2005 - 2010 15
Table 6: Gaucher's Disease Therapeutics Market, The US, Forecasts ($m), 2010 - 2018 16
Table 7: Gaucher's Disease Therapeutics Market, France, Revenue ($m), 2005 - 2010 17
Table 8: Gaucher's Disease Therapeutics Market, France, Forecasts ($m), 2010 - 2018 18
Table 9: Gaucher's Disease Therapeutics Market, Germany, Revenue ($m), 2005 - 2010 19
Table 10: Gaucher's Disease Therapeutics Market, Germany, Forecasts ($m), 2010 - 2018 20
Table 11: Gaucher's Disease Therapeutics Market, Italy, Revenue ($m), 2005 - 2010 21
Table 12: Gaucher's Disease Therapeutics Market, Italy, Forecasts ($m), 2010 - 2018 22
Table 13: Gaucher's Disease Therapeutics Market, Spain, Revenue ($m), 2005 - 2010 23
Table 14: Gaucher's Disease Therapeutics Market, Spain, Forecasts ($m), 2010 - 2018 24
Table 15: Gaucher's Disease Therapeutics Market, The UK, Revenue ($m), 2005 - 2010 25
Table 16: Gaucher's Disease Therapeutics Market, The UK, Forecasts ($m), 2010 - 2018 26
Table 17: Gaucher's Disease Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 27
Table 18: Gaucher's Disease Therapeutics Market, Japan, Forecasts ($m), 2010 - 2018 28
Table 19: Major Marketed Products in Gaucher's Disease Therapeutics Market 32
Table 20: Gaucher's Disease Therapeutics - Regulatory Filed and Phase III Pipeline, 2011 38
Table 21: Gaucher's Disease Therapeutics - Phase II Pipeline, 2011 38
Table 22: Gaucher's Disease Therapeutics - Preclinical Phase Pipeline, 2011 38
Table 23: Gaucher's Disease Therapeutics - Most Promising Drug in Clinical Development, 2011 40
Table 24: Gaucher's Disease Therapeutics - Clinical Trials by Country, 2011 44
Table 25: Gaucher's Disease Therapeutics - Clinical Trials by Phase, 2011 45
Table 26: Gaucher's Disease Therapeutics - Clinical Trials by Status, 2011 46
Table 27: Gaucher's Disease Therapeutics - Overall Sponsors, 2011 47
Table 28: Gaucher's Disease Therapeutics - Prominent Sponsors, 2011 48
Table 29: Gaucher's Disease Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 49
Table 30: Pfizer Inc., Pipeline - 2011 53
Table 31: Protalix BioTherapeutics, Inc., Pipeline - 2011 54
Table 32: ISU ABXIS Co., Ltd., Pipeline - 2011 55
Table 33: Gaucher's Disease - Global, Deals, 2011 59
List of Figures
Figure 1: Gaucher's Disease Therapeutics Market, Global, Revenue ($m), 2005 - 2010 12
Gaucher's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 4/7

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Figure 2: Gaucher's Disease Therapeutics Market, Global, Forecast ($m), 2010 - 2018 13
Figure 3: Gaucher's Disease Therapeutics Market, The US, Forecast ($m), 2005 - 2010 15
Figure 4: Gaucher's Disease Therapeutics Market, The US, Forecasts ($m), 2010 - 2018 16
Figure 5: Gaucher's Disease Therapeutics Market, France, Revenue ($m), 2005 - 2010 17
Figure 6: Gaucher's Disease Therapeutics Market, France, Forecast ($m), 2010 - 2018 18
Figure 7: Gaucher's Disease Therapeutics Market, Germany, Revenue ($m), 2005 - 2010 19
Figure 8: Gaucher's Disease Therapeutics Market, Germany, Forecast ($m), 2010 - 2018 20
Figure 9: Gaucher's Disease Therapeutics Market, Italy, Revenue ($m), 2005 - 2010 21
Figure 10: Gaucher's Disease Therapeutics Market, Italy, Forecast ($m), 2010 - 2018 22
Figure 11: Gaucher's Disease Therapeutics Market, Spain, Revenue ($m), 2005 - 2010 23
Figure 12: Gaucher's Disease Therapeutics Market, Spain, Forecast ($m), 2010 - 2018 24
Figure 13: Gaucher's Disease Therapeutics Market, The UK, Revenue ($m), 2005 - 2010 25
Figure 14: Gaucher's Disease Therapeutics Market, The UK, Forecast ($m), 2010 - 2018 26
Figure 15: Gaucher's Disease Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 27
Figure 16: Gaucher's Disease Therapeutics Market, Japan, Forecasts ($m), 2010 - 2018 28
Figure 17: Opportunity and Unmet Need in the Gaucher's Disease Therapeutics Market 31
Figure 18: Gaucher's Disease Therapeutics - Strategic Competitor Assessment, 2011 32
Figure 19: Gaucher's Disease Therapeutics - Pipeline by Phase of Development, 2011 37
Figure 20: Gaucher's Disease Therapeutics - Technology Trends Analytics Framework, 2011 39
Figure 21: Gaucher's Disease Therapeutics - Technology Trends Analytics Framework - Description, 2011 39
Figure 22: Gaucher's Disease Therapeutics - Pipeline by Mechanism of Action, 2011 40
Figure 23: Gaucher's Disease Therapeutics - Clinical Trials by Country, 2011 44
Figure 24: Gaucher's Disease Therapeutics - Clinical Trials by Phase, 2011 45
Figure 25: Gaucher's Disease Therapeutics - Clinical Trials by Status, 2011 46
Figure 26: Gaucher's Disease Therapeutics - Overall Sponsors, 2011 47
Figure 27: Gaucher's Disease Therapeutics - Prominent Sponsors, 2011 48
Figure 28: Gaucher's Disease Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 49
Figure 29: Gaucher's Disease Therapeutics Market, Drivers and Barriers, 2011 50
Figure 30: Implications for Future Market Competition in the Gaucher's Disease Therapeutics Market, 2011 51
Figure 31: Gaucher's Disease Therapeutics Market - Clinical Pipeline by Company, 2011 52
Figure 32: GlobalData Market Forecasting Model 64
Companies mentioned
Pfizer Inc.
Protalix BioTherapeutics, Inc.
ISU ABXIS Co., Limited
Sanofi
Actelion Limited
Shire Plc
Gaucher's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 5/7

6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Gaucher's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 3 500.00 Quantity: _____
Site License--USD 7 000.00 Quantity: _____
Corporate License--USD 10 500.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Gaucher's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 6/7

7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Gaucher's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 7/7